Publications by authors named "L L Girshova"
Article Synopsis
- The COMMODORE trial tested a new drug called gilteritinib against a treatment called salvage chemotherapy for patients with a type of blood cancer (AML) that has a specific gene mutation (FLT3).
- Results showed that patients taking gilteritinib lived longer (9.6 months) than those on chemotherapy (5.0 months) and also stayed healthier for longer without problems (2.8 months vs. 0.6 months).
- Gilteritinib led to fewer severe side effects, with common issues being low red blood cells and low platelet levels, making it a safer option for these patients.
Mutations in the gene not only lead to abnormalities in its structure and function, but also affect the expression of other genes involved in leukemogenesis. This study evaluated the expression of genes that are more characteristic of neuroblastoma but less studied in leukemia. oncogene expression was found to be more than 3-fold higher in primary AML patients carrying the mutation compared to carriers of other mutations as well as patients with normal karyotype ( = 0.
View Article and Find Full Text PDFPANTHER is a global, randomized phase 3 trial of pevonedistat+azacitidine (n = 227) vs azacitidine monotherapy (n = 227) in patients with newly diagnosed higher-risk myelodysplastic syndromes (MDS; n = 324), higher-risk chronic myelomonocytic leukemia (n = 27), or acute myeloid leukemia (AML) with 20% to 30% blasts (n = 103). The primary end point was event-free survival (EFS). In the intent-to-treat population, the median EFS was 17.
View Article and Find Full Text PDFThe phase 3 MIRROS (MDM2 antagonist Idasanutlin in Relapsed or Refractory acute myeloid leukemia [AML] for Overall Survival) trial (NCT02545283) evaluated the efficacy and safety of the small-molecule MDM2 antagonist idasanutlin plus cytarabine in patients with relapsed/refractory (R/R) AML. Adults (n = 447) with R/R AML whose disease relapsed or was refractory after ≤2 prior induction regimens as initial treatment or following salvage chemotherapy regimen, with Eastern Cooperative Oncology Group performance status ≤2 were enrolled regardless of TP53 mutation status and randomly assigned 2:1 to idasanutlin 300 mg or placebo orally twice daily plus cytarabine 1 g/m2 IV on days 1 to 5 of 28-day cycles. At primary analysis (cutoff, November 2019), 436 patients were enrolled, including 355 in the TP53 wild-type intention-to-treat (TP53WT-ITT) population.
View Article and Find Full Text PDFHealthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international study.
Eur J Haematol
July 2022
Article Synopsis
- A retrospective chart review studied healthcare resource utilization (HRU) in patients with AML who couldn't receive intensive therapy, focusing on those who were treated with first-line systemic therapies or best supportive care.
- Among the 1762 patients analyzed, the majority were hospitalized primarily for treatment-related reasons, with the highest hospitalization rates seen in those receiving hypomethylating agents (HMA) and low-dose cytarabine (LDAC).
- The results indicated a significant demand for hospitalizations, transfusions, and outpatient consultations, highlighting the necessity for new treatment options to reduce the healthcare burden on these patients.